BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21911597)

  • 1. FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study.
    Hoitsma AJ; Woodle ES; Abramowicz D; Proot P; Vanrenterghem Y;
    Nephrol Dial Transplant; 2011 Nov; 26(11):3802-5. PubMed ID: 21911597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation.
    Tedesco-Silva H; Pescovitz MD; Cibrik D; Rees MA; Mulgaonkar S; Kahan BD; Gugliuzza KK; Rajagopalan PR; Esmeraldo Rde M; Lord H; Salvadori M; Slade JM;
    Transplantation; 2006 Dec; 82(12):1689-97. PubMed ID: 17198261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study.
    Tedesco-Silva H; Szakaly P; Shoker A; Sommerer C; Yoshimura N; Schena FP; Cremer M; Hmissi A; Mayer H; Lang P;
    Transplantation; 2007 Oct; 84(7):885-92. PubMed ID: 17984842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
    Tedesco-Silva H; Mourad G; Kahan BD; Boira JG; Weimar W; Mulgaonkar S; Nashan B; Madsen S; Charpentier B; Pellet P; Vanrenterghem Y
    Transplantation; 2005 Jun; 79(11):1553-60. PubMed ID: 15940045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia.
    Salvadori M; Budde K; Charpentier B; Klempnauer J; Nashan B; Pallardo LM; Eris J; Schena FP; Eisenberger U; Rostaing L; Hmissi A; Aradhye S;
    Am J Transplant; 2006 Dec; 6(12):2912-21. PubMed ID: 17061999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
    Tedesco-Silva H; Mourad G; Kahan BD; Boira JG; Weimar W; Mulgaonkar S; Nashan B; Madsen S; Charpentier B; Pellet P; Vanrenterghem Y
    Transplantation; 2004 Jun; 77(12):1826-33. PubMed ID: 15223899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
    Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID; Kelly DA
    Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study.
    Tedesco-Silva H; Lorber MI; Foster CE; Sollinger HW; Mendez R; Carvalho DB; Shapiro R; Rajagopalan PR; Mayer H; Slade J; Kahan BD;
    Clin Transplant; 2009; 23(5):589-99. PubMed ID: 19719728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients.
    Oppenheimer F; Mulgaonkar S; Ferguson R; Grinyó J; Juarez F; Ostrowski M; Klinger M; Walker R; Torres A; Preiss R; Cremer M; Jardine A;
    Transplantation; 2007 Mar; 83(5):645-8. PubMed ID: 17353787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial.
    Huh KH; Lee JG; Ha J; Oh CK; Ju MK; Kim CD; Cho HR; Jung CW; Lim BJ; Kim YS;
    Nephrol Dial Transplant; 2017 Aug; 32(8):1415-1424. PubMed ID: 28810721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
    Pham PT; Pham PC
    Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients.
    Westhoff TH; Schmidt S; Glander P; Liefeld L; Martini S; Offermann G; Neumayer HH; Zidek W; van der Giet M; Budde K
    Nephrol Dial Transplant; 2007 Aug; 22(8):2354-8. PubMed ID: 17526535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study.
    Mulgaonkar S; Tedesco H; Oppenheimer F; Walker R; Kunzendorf U; Russ G; Knoflach A; Patel Y; Ferguson R;
    Am J Transplant; 2006 Aug; 6(8):1848-57. PubMed ID: 16771816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
    Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.